Jim Simons Vascular Biogenics Ltd. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.11 - $0.16 $7,491 - $10,896	-68,100 Reduced 20.48%	264,500 $32,000
Q3 2022 Nov 14, 2022	BUY	$0.15 - $2.1 $49,890 - $698,460	332,600 New	332,600 $52,000
Q2 2021 Aug 13, 2021	SELL	$1.69 - $2.67 $128,102 - $202,386	-75,800 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$1.79 - $2.91 $791,896 - $1.29 Million	-442,400 Reduced 85.37%	75,800 $152,000
Q4 2020 Feb 10, 2021	SELL	$1.07 - $2.0 $101,486 - $189,694	-94,847 Reduced 15.47%	518,200 $979,000
Q3 2020 Nov 13, 2020	BUY	$1.11 - $1.4 $11,004 - $13,879	9,914 Added 1.64%	613,047 $748,000
Q2 2020 Aug 13, 2020	BUY	$1.12 - $1.63 $513,556 - $747,408	458,533 Added 317.1%	603,133 $772,000
Q1 2020 May 14, 2020	BUY	$0.96 - $1.57 $104,625 - $171,106	108,985 Added 306.01%	144,600 $195,000
Q4 2019 Feb 13, 2020	BUY	$1.1 - $1.32 $17,603 - $21,123	16,003 Added 81.6%	35,615 $43,000
Q3 2019 Nov 13, 2019	SELL	$1.11 - $1.42 $16,969 - $21,708	-15,288 Reduced 43.81%	19,612 $26,000
Q2 2019 Aug 12, 2019	BUY	$1.16 - $1.53 $24,244 - $31,977	20,900 Added 149.29%	34,900 $45,000
Q1 2019 May 14, 2019	BUY	$0.94 - $1.75 $13,160 - $24,500	14,000 New	14,000 $21,000

416K

Ticker VBLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,348,896
Description
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antib...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.